WO2025114919 - MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGER COMBINATION THERAPY FOR TREATING HEMATOLOGICAL NEOPLASTIC DISORDERS
National phase entry is expected:
Publication Number
WO/2025/114919
Publication Date
05.06.2025
International Application No.
PCT/IB2024/061945
International Filing Date
27.11.2024
Title **
[English]
MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGER COMBINATION THERAPY FOR TREATING HEMATOLOGICAL NEOPLASTIC DISORDERS
[French]
POLYTHÉRAPIE PAR ACTIVATION DE CELLULES TUEUSES NATURELLES MULTIFONCTIONNELLES (NK) POUR LE TRAITEMENT DE TROUBLES NÉOPLASIQUES HÉMATOLOGIQUES
Applicants **
SANOFI
Inventors
ABBADESSA, Giovanni
CHIRON, Marielle
FRAENKEL, Paula
VIRONE-ODDOS, Angela
Priority Data
23307073.9
28.11.2023
EP
24306298.1
31.07.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3821 | |
| EPO | Filing, Examination, Granting | 28610 | |
| Japan | Filing, Examination, Granting | 3239 | |
| South Korea | Filing, Examination, Granting | 4160 | |
| USA | Filing, Examination, Granting | 13990 |
Total:
53,820
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to methods for treating or preventing a leukemia or a myelodysplastic syndrome in a subject in need thereof, said method comprising administering to the subject an effective amount of a combination comprising: (i) a binding protein comprising a first antigen binding domain (ABD) with binding specificity to CD123 and a second (ABD) with binding specificity to NKp46; and one or both of: (ii) a BCL-2 inhibitor, and (iii) a DNA hypomethylating agent.[French]
La présente divulgation concerne des méthodes de traitement ou de prévention d'une leucémie ou d'un syndrome myélodysplasique chez un sujet en ayant besoin, ladite méthode comprenant l'administration au sujet d'une quantité efficace d'une combinaison comprenant : (i) une protéine de liaison comprenant un premier domaine de liaison à l'antigène (ABD) ayant une spécificité de liaison à CD123 et une seconde (ABD) ayant une spécificité de liaison à NKp46 ; et l'un ou les deux parmi : (ii) un inhibiteur de BCL-2, et (iii) un agent d'hypométhylation d'ADN.